Clark Estates Inc. NY Decreases Stake in Haleon plc (NYSE:HLN)

Clark Estates Inc. NY cut its stake in Haleon plc (NYSE:HLN - Free Report) by 24.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,000,000 shares of the company's stock after selling 650,000 shares during the period. Haleon makes up approximately 3.9% of Clark Estates Inc. NY's holdings, making the stock its 6th biggest position. Clark Estates Inc. NY's holdings in Haleon were worth $21,160,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. FMR LLC increased its stake in Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company's stock valued at $1,110,035,000 after acquiring an additional 5,768,117 shares during the period. Sculptor Capital LP grew its holdings in shares of Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company's stock worth $73,407,000 after purchasing an additional 3,592,000 shares in the last quarter. Clearbridge Investments LLC increased its position in shares of Haleon by 8.6% during the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company's stock valued at $344,888,000 after purchasing an additional 3,307,009 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Haleon by 95.5% in the second quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company's stock valued at $16,143,000 after purchasing an additional 954,622 shares in the last quarter. Finally, Natixis Advisors LLC lifted its position in Haleon by 142.5% in the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company's stock worth $15,593,000 after purchasing an additional 866,070 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HLN has been the topic of several analyst reports. Morgan Stanley boosted their price target on shares of Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a report on Friday, September 20th. Berenberg Bank initiated coverage on shares of Haleon in a research report on Tuesday, August 6th. They issued a "buy" rating for the company. UBS Group upgraded shares of Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. Finally, The Goldman Sachs Group lowered Haleon from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 6th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $10.95.

Haleon Price Performance

HLN stock traded up $0.13 during trading on Wednesday, hitting $9.72. 5,935,202 shares of the stock traded hands, compared to its average volume of 5,314,853. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a market cap of $44.00 billion, a price-to-earnings ratio of 28.21, a P/E/G ratio of 2.89 and a beta of 0.30. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company has a 50 day simple moving average of $9.97 and a 200 day simple moving average of $9.41.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.